Medline (NASDAQ:MDLN) Stock Price Target Raised at Citigroup

Medline (NASDAQ:MDLN) had its price objective boosted by Citigroup from $45.00 to $47.00 in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also weighed in on MDLN. Royal Bank Of Canada lowered their price objective on shares of Medline from $53.00 to $46.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Weiss Ratings downgraded Medline from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, October 8th. Deutsche Bank Aktiengesellschaft set a $37.00 target price on Medline and gave the company a “hold” rating in a research report on Thursday, August 6th. Mizuho lowered their target price on Medline from $48.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, October 22nd. Finally, Robert W. Baird set a $42.00 target price on Medline in a report on Thursday, August 6th. Twenty-three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Medline presently has a consensus rating of “Moderate Buy” and an average price target of $46.08.

Medline Price Performance

Shares of NASDAQ MDLN opened at $39.76 on Thursday. The company has a quick ratio of 2.61, a current ratio of 4.33 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $52.27 billion and a PE ratio of 33.35. The firm has a fifty day simple moving average of $34.68 and a 200 day simple moving average of $39.51. Medline has a twelve month low of $31.37 and a twelve month high of $50.88.

Medline (NASDAQ:MDLN) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The firm had revenue of $7.86 billion during the quarter. Medline had a return on equity of 8.22% and a net margin of 1.84%. On average, sell-side analysts forecast that Medline will post 1.49 EPS for the current year.

Insiders Place Their Bets

In other Medline news, major shareholder Private Ltd Gic sold 2,570,999 shares of Medline stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the transaction, the insider directly owned 20,231,483 shares of the company’s stock, valued at $715,182,924.05. The trade was a 11.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 7,948,676 shares of company stock worth $281,805,137. 0.81% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Medline

A number of institutional investors have recently added to or reduced their stakes in MDLN. GAMMA Investing LLC increased its position in shares of Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after acquiring an additional 254 shares during the last quarter. Whipplewood Advisors LLC purchased a new stake in shares of Medline during the 1st quarter valued at $30,000. Reyes Financial Architecture Inc. bought a new stake in shares of Medline during the 3rd quarter worth $30,000. NewEdge Advisors LLC boosted its holdings in shares of Medline by 100.0% in the 2nd quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock worth $37,000 after buying an additional 475 shares during the last quarter. Finally, Allworth Financial LP increased its holdings in Medline by 86.2% during the second quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock worth $41,000 after buying an additional 487 shares during the last quarter.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported third-quarter EPS of $0.44, above the $0.32 consensus, on $7.86 billion in revenue. Reports also said the company raised its full-year growth outlook. Medline Q3 results
• Positive Sentiment: Several analysts raised price targets and maintained bullish ratings: UBS to $49, Citi to $47, and Leerink Partners to $46; BTIG reaffirmed Buy with a $55 target. These actions signal continued confidence in the stock’s potential. Read More., Read More., Read More., Read More.
• Positive Sentiment: Medline plans to raise prices in 2027 to help offset inflation, and reports cited a $1 billion share-buyback plan—both potential supports for financial performance and shareholder returns. Pricing and Q3 results
• Negative Sentiment: Despite the EPS beat, one report said quarterly profit fell, while Medline reaffirmed its full-year adjusted EBITDA outlook rather than raising it. That may have tempered the positive reaction to the results. Q3 profit and outlook report
• Negative Sentiment: A law firm announced an investigation into potential securities-fraud claims related to alleged product-quality issues. This is an allegation and investigation announcement, not a finding of wrongdoing, but it could add uncertainty for investors. Investigation announcement

About Medline

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.